Glutamine transporters as effective targets in digestive system malignant tumor treatment.

IF 2 4区 医学 Q3 ONCOLOGY Oncology Research Pub Date : 2024-09-18 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.048287
Fei Chu, Kai Tong, Xiang Gu, Mei Bao, Yanfen Chen, Bin Wang, Yanhua Shao, Ling Wei
{"title":"Glutamine transporters as effective targets in digestive system malignant tumor treatment.","authors":"Fei Chu, Kai Tong, Xiang Gu, Mei Bao, Yanfen Chen, Bin Wang, Yanhua Shao, Ling Wei","doi":"10.32604/or.2024.048287","DOIUrl":null,"url":null,"abstract":"<p><p>Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively low survival rate and severe side effects associated with DSMTs treatment, new treatment strategies are urgently required. This article summarizes the glutamine transporters involved in DSMTs and describes their role in DSMTs. Additionally, glutamine transporter-target drugs are discussed, providing theoretical guidance for the further development of drugs DSMTs treatment.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 10","pages":"1661-1671"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413814/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.048287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively low survival rate and severe side effects associated with DSMTs treatment, new treatment strategies are urgently required. This article summarizes the glutamine transporters involved in DSMTs and describes their role in DSMTs. Additionally, glutamine transporter-target drugs are discussed, providing theoretical guidance for the further development of drugs DSMTs treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
谷氨酰胺转运体是消化系统恶性肿瘤治疗的有效靶点。
谷氨酰胺是人体血浆中含量最高的非必需氨基酸之一,在人体的许多生物过程中发挥着至关重要的作用。肿瘤细胞会吸收大量谷氨酰胺以满足其快速增殖的需要,而谷氨酰胺转运体的上调则支持了这一点。靶向抑制谷氨酰胺转运体可有效抑制肿瘤细胞的生长和增殖。在所有癌症中,消化系统恶性肿瘤(DSMTs)的发病率和死亡率最高,目前针对DSMTs的治疗策略主要是手术切除和化疗。由于 DSMTs 的生存率相对较低,且治疗过程中会产生严重的副作用,因此迫切需要新的治疗策略。本文总结了参与 DSMTs 的谷氨酰胺转运体,并描述了它们在 DSMTs 中的作用。此外,还讨论了谷氨酰胺转运体靶向药物,为进一步开发治疗 DSMTs 的药物提供理论指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
期刊最新文献
Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer. CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma. A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development. hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1